Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers

doi:10.1038/sj.bjc.6600697

PMC full text:

Br J Cancer. 2003 Feb 24; 88(4): 530–536.

Published online 2003 Feb 18. doi: 10.1038/sj.bjc.6600697

Copyright/LicenseRequest permission to reuse: Copyright © 2003 Cancer Research UK
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

<< PrevFigure 2Next >>

Figure 2

An external file that holds a picture, illustration, etc.
Object name is 88-6600697f2.jpg

IFN-γ production in T-cell response against Ki-ras peptides in colorectal cancer patients. IFN-γ production in colorectal cancer patients: (7) Ki-ras mutation (−) (DR4, 6; DQ1, 4) (1) Ki-ras mutation (D) (DR1, 8; DQ1) (2) Ki-ras mutation (D); (8) Ki-ras mutation (−) (DR8, 12; DQ3, 4) (9) Ki-ras mutation (−) (DR2,6; DQ1); (10) Ki-ras mutation (−) (DR2,6; DQ1,3); (11) Ki-ras mutation (−) (DR1, 4; DQ1, 3)~ (4) Ki-ras mutation (V) (DR8; DQ1, 3); (12) Ki-ras mutation (−) (DR6; 9 DQ1). The numbers (1–4) of supernatants indicate the period of exposure of T-cells exposed to Ki-ras peptides. Supernatants 1, 2, 3 and 4 were collected on days 5, 10, 15 and 20 after primary stimulation, respectively.

Figure 2

Images in this article

Click on the image to see a larger version.